Navigation Links
Activity Against Drug-Resistant Pathogens is One of the Leading Attributes Influencing Physicians' Antibiotic Selection for the Treatment of Inpatient Community-Acquired Pneumonia
Date:2/24/2009

Future Therapies Modeled After Johnson & Johnson/Basilea's or Forest/Novexel's Drug Could Be Used As First-Line Therapies, According to a New Report from AMR and Decision Resources

MALVERN, Pa. and WALTHAM, Mass., Feb. 24 /PRNewswire/ -- Arlington Medical Resources (AMR) and Decision Resources find that activity against drug-resistant pathogens is one of the leading drug attributes influencing surveyed physicians' antibiotic selection for the treatment of inpatient community-acquired pneumonia. Due to the difficulty of obtaining adequate samples for microbiological testing, physicians rely on empiric therapies that can cover key pathogens, particularly resistant and susceptible strains of Streptococcus pneumoniae. In fact, one of the key trends surveyed physicians foresee in the next five years is to prescribe an empiric therapy that covers methicillin-resistant Staphylococcus aureus (MRSA) for inpatients with community-acquired pneumonia.

The new report entitled Hospital Anti-Infectives Insight Series: Community-Acquired Pneumonia also finds that future therapies modeled after Johnson & Johnson/Basilea's ceftobiprole or Forest/Novexel's ceftaroline could be used as empiric first-line therapies for very severe cases of community-acquired pneumonia requiring admission to the ICU or mechanical ventilation.

"Ceftobiprole and ceftaroline couple broad-spectrum cephalosporin activity with targeted activity against MRSA, offering physicians enhanced pathogen coverage for empiric treatment of community-acquired pneumonia in the hospital setting," stated Lisa Arias, analyst at Decision Resources. "We anticipate that future therapies modeled after these agents will gain substantial usage in the market for the treatment of inpatient community-acquired pneumonia and potentially displace usage of older, generically available cephalosporins, due to their anti-MRSA activity."

About Hospital Anti-Infectives Insight Series

AMR and Decision Resources' new Hospital Anti-Infectives Insight Series analyzes hospital antibiotic prescribing patterns using AMR's comprehensive and highly detailed clinical data in conjunction with Decision Resources' disease area knowledge, primary research and extensive understanding of emerging therapies and forecasts. These reports examine the reasons behind physicians' product preferences, factors driving hospital antibiotic prescribing patterns and receptivity to emerging antibiotics.

About AMR

AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Natalia Morales                 Elizabeth Marshall
    Decision Resources              Decision Resources, Inc.
    781-296-2691                    781-296-2563
    nmorales@dresources.com         emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Physical activity guidelines are too confusing, say researchers
2. CRH experiences significant increase in business activity
3. Flu Activity Increases in the U.S.
4. Durability of dental fillings improves if the enzyme activity of teeth is inhibited
5. Regular physical activity linked to better quality of life in early-stage lung cancer survivors
6. Huron Capital Continues Acquisition Activity
7. Altered brain activity in schizophrenia may cause exaggerated focus on self
8. School-based physical activity: Has benefits even if it doesnt help lose weight
9. Radiotherapy Clinics of Georgia and NewsTalk 750 WSB Team Up to Promote Prostate Proactivity
10. Reduced breast cancer risk: Physical activity after menopause pays off
11. Physical activity, mood and serious mental illness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical ... be the preferred physical therapy provider for Derby City CrossFit, effective immediately. , ... CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists will work ...
(Date:4/25/2017)... ... 25, 2017 , ... A recent report from the Wisconsin ... the 2015-16 school year across Wisconsin’s public schools, charter schools, and private schools ... in student test score performance, the report’s limited analyses fail to provide answers ...
(Date:4/25/2017)... ... 25, 2017 , ... As pharmaceutical companies are held to ... process innovation in drug formulation and manufacturing. CoreRx offers its clients more ... in support of their development and manufacturing goals. , The company was ...
(Date:4/25/2017)... ... ... MD is committed to providing the highest quality of spine care to all his patients. ... all my patients to alleviate possible future issues. I am pleased to have you as ... my trained staff will assist you in any way possible.” , Dr. Saad Chaudhary is ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® , ... Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day ... at the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017 Eyevensys, a ... first non-viral gene expression technology that enables the safe, ... to address a wide range of ophthalmic diseases, announces ... Healthcare products Regulatory Agency (MHRA) to advance its technology ... ...
(Date:4/19/2017)... 2017 The Mobile X-Ray product segment is the ... during the forecast period Mobile X-Ray segment is ... mobile X-Ray devices market, which is estimated to be valued ... a CAGR of 7% over the forecast period. Mobile X-Ray ... than US$ 100 Mn in 2017 over 2016. The segment,s ...
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market ... has covered and analysed the potential of Global Effective Microorganisms ... shares and growth factors. The report identifies and analyses the ... the global market. ... 152 Tables and Figures, 6 Major Company Profiles, spread across ...
Breaking Medicine Technology: